ESR1 and breast cancer: Together, these observations suggest that anti-estrogen treatment, the standard of care for patients with ER+ breast cancer, may complement RT by reducing recruitment/ activity of suppressive immune cell populations, resulting in increased anti-tumor immunity and responsiveness to ICIs.